Wells Fargo downgraded Zentalis Pharma from Overweight to Equal Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2024 | $4.00 | Underperform → Neutral | Wedbush |
| 6/20/2024 | $28.00 → $5.00 | Buy → Neutral | UBS |
| 6/18/2024 | $42.00 → $6.00 | Buy → Hold | Jefferies |
| 6/18/2024 | $38.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/18/2024 | $15.00 → $4.00 | Neutral → Underperform | Wedbush |
| 6/18/2024 | Overweight → Equal Weight | Wells Fargo | |
| 11/8/2023 | $38.00 → $12.00 | Outperform → Neutral | Wedbush |
| 11/7/2023 | $15.00 | Outperform → Market Perform | Leerink Partners |
Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced changes to its executive leadership team to support the Company as it plans and executes registrational studies for its lead product candidate, azenosertib. Julie Eastland has been appointed Chief Executive Officer, Pres
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company's common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib, the Company's novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study a
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2024, and highlighted recent corporate accomplishments. "While we faced challenges this quarter with regards to the ongoing partial clinical hold on azenosertib, we remain steadfast in our confidence in the program's t
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies. "We are pleased to have Luke join our Board of Directors and contribute to the Company's pipeline
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis' long-term portfolio strategy. Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway. "Kimberly brings an o
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00
UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
144 - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
Zentalis Pharma's (NYSE:ZNTL) short percent of float has fallen 5.5% since its last report. The company recently reported that it has 17.51 million shares sold short, which is 49.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 32.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inter
UBS analyst Eliana Merle downgrades Zentalis Pharma (NASDAQ:ZNTL) from Buy to Neutral and lowers the price target from $28 to $5.
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha